In triple negative breast cancer, lacking HER2, estrogen or progesterone receptors, the opioids growth factors (OGF) and its receptor pathway is present and regulates cell proliferation both physiologically and pathologically. This evidence concerns the gene PGR and triple-negative breast carcinoma.